CORE-017: CLINICAL PROTOCOL AND DATA MANAGEMENT (CPDM) PROJECT SUMMARY / ABSTRACT The Clinical Protocol and Data Management (CPDM) function of the OSUCCC provides comprehensive resources for the conduct of cancer clinical research with an emphasis on the inclusion of women, minorities, children and other underserved populations. The CPDM is overseen by Dr. William Carson, the Associate Director for Clinical Research (ADCR). The cancer center's Clinical Trials Office (CTO), supports the centralized administration of protocol development, implementation and conduct for all clinically active cancer research groups. No clinical cancer research may be conducted outside the CTO. Thus, the CTO oversees all cancer clinical trials and is the centralized organization for the conduct of such research. This team provides the trial administration, protocol tracking and monitoring, data management, regulatory processing and financial supervision necessary for the successful conduct of clinical trials in a methodologically-sound, expedient, and cost-effective manner. The CTO Medical Director is Steven Devine, MD and the CTO Medical Co-Director is Dr. Bhuvana Ramaswamy, MD. The CTO interim Administrative Director is Nancy Single, PhD. The OSUCCC Data and Safety Monitoring Plan outlines the structure and responsibilities of the Data and Safety Monitoring Committee (DSMC) which oversees and reviews the safe conduct of clinical research at this cancer center. The DSMC is headed by William Blum, MD. The inclusion of women, minorities and children in cancer clinical research is an important goal of this organization and effort in this area are coordinated by the Center for Cancer Health Equity under the leadership of Electra Paskett, PhD, OSUCCC Associate Director for Population Sciences.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-40
Application #
9000516
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-09-12
Project End
2020-11-30
Budget Start
2016-02-09
Budget End
2016-11-30
Support Year
40
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Pan, Pan; Oshima, Kiyoko; Huang, Yi-Wen et al. (2018) Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. Int J Cancer 143:886-896

Showing the most recent 10 out of 2602 publications